Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease.
Ting Yu, Shanshan Liu, Jing Zhao and 2 others
PMID 38352295WHAT IT FOUND
In 366 hospitalized patients with chronic liver disease, the Ishii score worked best among four screening tools: it caught 85.94% of sarcopenia cases and was correct in 78.15% of patients without sarcopenia.
Use it to screen, not diagnose.
Key findings
01Sarcopenia was present in 17.5% (64/366) of the enrolled chronic liver disease patients when assessed by AWGS 2019.
02The Ishii score had the best screening performance among the four tools, with sensitivity 85.94%, specificity 78.15%, AUC 0.82 and Youden index 0.64.
03SARC-F had the lowest sensitivity (6.25%) and the highest specificity (99.34%) among the four tools.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The authors state the sample size is relatively small, especially for subgroup analysis. The participants were hospitalized patients with chronic liver disease, mainly Child-Pugh B or C, so the findings may not apply to community adults or milder disease. The study was done at a general hospital in Sichuan, and the authors call for larger studies to validate the results. The paper reports screening accuracy only, not whether using these tools improved patient outcomes.
Declared interests
Nothing to declare; the authors declare no conflicts of interest.
The easy way to misread this
Do not treat a positive Ishii score as a confirmed diagnosis of sarcopenia. It was compared with the AWGS 2019 reference, and the authors say larger studies are needed to validate the results.